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with and without shield attenuation using TG43 and were 
calculated with TG186 fixing the dwell times. It was not 
possible to perform a TG186 calculation without the shields 
in place. The TG186 calculation used a HU based mass 
density and all contoured organs were set to ‘female soft 
tissue’ except bladder which was set to ‘water’ to provide 
the chemical composition.  
The HRCTV D90 and D2cc for rectum, bladder, small bowel 
and sigmoid were recorded and EQD2 doses calculated 
assuming 50.4Gy in 28 fractions external beam component. 
 
Results: Table 1 gives the difference in HRCTV D90 and OAR 
D2cc doses between the different dose calculations.  
 
 
 
The combination of shields and TG186 dose calculation 
reduced the rectum D2cc by an average of 15.8% (5.6%-
31.7%) compared to the TG43 dose calculation with no shields 
in place. This equates to a reduction in EQD2 of 4.2Gy 
(0.6Gy-13Gy) and is associated with an average HRCTV EQD2 
reduction of 1Gy. The reduction is due to the physical effect 
of the shielding and the more accurate dose calculation. 
These results show that the effect of the algorithm is the 
largest contributor as TG43 underestimates the effect of the 
shields. 
 
Conclusion: This study demonstrates that using shielded 
applicators has the potential to reduce the rectum D2cc. The 
rectal dose is rarely our dose limiting organ due to the 
routine use of a rectal retractor, however any reduction in 
rectal dose would be beneficial. Two patients in this cohort 
had rectal D2cc doses greater than 70Gy in the clinical plan. 
For these two patients the shielded TG186 plan reduced the 
rectal D2cc dose significantly by 5.7Gy and 13Gy compared to 
the unshielded TG43 plan. Further work is needed to assess 
the TG186 calculation without shields and the effect of 
applicator geometry on the position of OARs. 
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Purpose or Objective: In vivo dosimetry (IVD) measurements 
in HDR brachytherapy (BT) have to be validated by 
performing a quality assurance check of the functionality of 
the dosimeters right after the treatment. Recalibration is 
also usually required due to the high delivered doses per 
fraction involved. The standard procedure using Ir-192 is 
burdensome due to limited availability of the operating 
theater, where the afterloader containing the Ir-192 source is 
located, as well as due to the transport and setup of the 
water equivalent phantom. In this work, a procedure 
involving the use of a certified low dose emitting Sr-90 source 
was proposed to both perform QA and recalibration of MOSkin 
dosimeters right after IVD in HDR Ir-192 BT without the need 
of the BT theater and phantom setup. 
 
Material and Methods: The MOSkin is a type of MOSFET 
detector developed at the Centre of Medical Radiation 
Physics (CMRP) in the University of Wollongong that was 
integrated into present HDR Ir-192 BT procedures for real 
time IVD. The standard MOSkin calibration/verification 
technique employs the Ir-192 source used in HDR procedures, 
in which case the detector is placed into a water equivalent 
phantom, and irradiated three times with a known dose. The 
average of the three measurements is calculated as the 
calibration coefficient. Instead of using Ir-192, in this study 
the use of a certified low dose emitting Sr-90 source was 
investigated. A very small phantom that allows a fixed 
position of the detector in relation to the source was 
established. Three MOSkins were tested at three stages of 
their lifetime, roughly 15 Gy apart. At each one of these 
stages, each MOSkin was calibrated by performing three 
measures both with Sr-90 and Ir-192. The sensitivity ratio of 
the average values obtained with Sr-90 and Ir192 was 
calculated for each measurement. 
 
Results: Both Sr-90 and Ir-192 measurements confirmed a 
small reduction of MOSkin sensitivity with accumulated dose, 
at 1.1% with every 10 Gy, which is proportional to the change 
in threshold voltage of the dosimeter to the first order of 
approximation. The sensitivity ratio of Sr-90 and Ir-192 
measurements remained at a constant value of 9.0±0.2% for 
all three stages of MOSkin life, and among the three 
dosimeters employed in the experiment. 
 
Conclusion: A stable proportional relationship was 
established between the Ir-192 and Sr-90 calibration 
methods, demonstrating that Sr-90 can be used effectively 
for MOSkin recalibration as well as for post treatment 
verification of their functionality after IVD sessions. The 
procedure involving Sr-90 is much more convenient because it 
does not necessitate the use of the BT operating theater and 
can be easily performed everywhere without any particular 
radioprotection requirements. Additionally it is not necessary 
to know the dose delivered by Ir-192 and Sr-90 to MOSkin but 
rather the time of irradiation of the MOSkin on each of them 
respectively, assuming activity changes of Sr-90 are 
negligible.  
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Purpose or Objective: In high-dose rate (HDR) 
brachytherapy, accurate dose delivery is highly dependent on 
the geometrical and temporal source positioning accuracy. In 
this study, we measured the source position and dwell time 
accuracy of the Varian GammaMedplus iX afterloader as well 
as the dead space of a variety of Varian applicators. 
 
Material and Methods: The source position and dwell time 
accuracy were optically measured using Varian’s source step 
viewer and a videocamera. The Perma-Doc phantom was used 
for dosimetric verification of the afterloader’s source 
positioning accuracy. The most distal source position and the 
dead space of the applicators (titanium/stainless steel/ 
plastic needles, titanium Fletcher-type and flexible tube) 
were measured radiographically using kV imaging and 
dosimetrically using EBT3 film. For these measurements an X-
ray marker and the Ir-192 source were successively inserted 
into the applicators, respectively. The distance between the 
external end of the applicators and the center of the most 
distal X-ray marker and the first dwell position on film were 
measured (Fig.1). 
 
Results: The dwell time deviation measured at different 
source positions is <0.1s, and is in accordance with vendor 
specifications. For the most proximal source position, a 
systematic longer dwell time of 0.13s was observed. This 
deviation should be negligible when multiple dwell positions 
are used. Position verification using the source step viewer 
shows deviations of 0.5–1mm (vendor specs: ± 1mm). At the 
most distal position, the source was always retracted by 1 
mm relative to the nominal position to straighten the source 
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cable. This effect was taken into account during treatment 
planning. Position verification using the PermaDoc phantom 
confirmed this 1 mm retraction. All radiographically 
measured dead spaces complied with the specifications, 
except for the plastic needles which were 1 mm shorter than 
indicated. The center of the active source is at 2.42 mm from 
the tip of the capsule. Combined with the 1 mm source 
retraction, the center of the dose distribution at the most 
distal position located always 3.5 mm behind the internal 
end-point of the source channel. Radiographic and dosimetric 
dead space measurements showed good agreement (<0.5mm) 
for all applicators.  
 
 
 
Conclusion: Measured source position and dwell time 
accuracy comply with the vendor’s specifications. Small 
deviations were found for the dwell time accuracy at the 
most proximal source position. Similar tests should be 
performed regularly to warrant the mechanical accuracy of 
the afterloader and the quality of the applicators and 
transfer tubes.  
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Purpose or Objective: Dose verification and quality 
assurance in radiotherapy (RT) should be assessed in order to 
provide the best treatment possible and minimize risks for 
patient. In certain treatments there are no tools capable of 
performing real-time dose measurement. In addition, in-situ 
real-time dosimetry would enhance brachytherapy (BT) by 
providing technical conditions to perform treatment 
readjustment and real-time dose correction. Considering the 
current challenges, we developed a dosimeter intended for 
in-situ and real-time dosimetry in High Dose Rate 
brachytherapy (HDR-BT), e.g., prostate and breast. 
 
Material and Methods: The dosimeter developed has a 
sensitive 3 m long optical fiber probe of 1mm or 0.5 mm 
diameter comprehending a 5 mm length scintillating optical 
fiber. To read the signal produced at the probe, 1x1 mm2 
Silicon Photomultipliers (SiPM) from Hamamatsu were used. A 
custom made readout system with SiPM temperature 
compensation was used. The main concerns when performing 
dosimetry at high dose rates with high energy isotopes is the 
eventuality of Cherenkov light production. This form of noise 
accounts to the total noise signal, known as stem effect. 
The dosimeter was placed in a PMMA phantom and the 
response was evaluated with a 10.07 Ci Ir-192 HDR-
brachytherapy source (Nucletron). Measurements were 
repeated twice, first using a dummy probe without 
scintillator for stem effect quantification and second using an 
ionization chamber (IC) read by an electrometer for 
reference. 
Results: The studies carried out allowed assessing the 
amount of stem effect produced in the optical fiber cable. In 
the conditions described above, the stem effect contribution 
is lower than 1% for both 0.5 and 1 mm probes. The 
measurements of the fiber dosimeter response as a function 
of the dose are represented in Figure 1. The small difference 
from the reference IC is due to the different detector 
volumes of the fiber dosimeter and the ionization chamber. 
The dosimeter shows a linear response with dose rate being 
capable of detecting µGy dose variations. 
 
 
 
Figure 1: Fiber optic dosimeter stem-effect and response for 
0.5 and 1 mm diameter versions compared to ionization 
chamber response. 
 
Conclusion: The first round of in-vitro tests in clinical setting 
demonstrated that the fiber optical based dosimeters 
developed are suitable for dosimetry in regimes such as HDR 
prostate BT. The versatility of this kind of device and 
easiness of use allows application in other radiotherapy 
modalities. Besides fulfilling all the requirements for a 
dosimeter in HDR-BT, the high sensitivity of this device 
makes it a suitable candidate for application in LDR-BT.  
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Purpose or Objective: An intraoperatively built custom-
linked (IBCL) seeds system is a push-button seed delivery 
system that allows the user to create intraoperatively 
customized linked seeds, using a combination of seeds, 
connectors, and spacers. To date, only three studies have 
compared the implant quality of IBCL seeds to loose seeds for 
use in permanent prostate brachytherapy (PPB). However, 
they did not use sector analysis. Therefore, we compared the 
implant quality of IBCL seeds to loose seeds in PPB using 
sector analysis. 
 
Material and Methods: Between June 2012 and January 2015, 
64 consecutive prostate cancer patients underwent 
brachytherapy with IBCL seeds (n = 32) or loose seeds (n = 
32). All the patients were treated with 144Gy of 
brachytherapy alone. IBCL and loose seeds were alternately 
used basically. All patients were treated by the same 
radiation oncologist and urologist. We used the same dose–
